	US 12,077,519 B2
	Heteroaryl carboxamide compound
Hideyuki Watanabe, Tokyo (JP); Takashi Kamikubo, Tokyo (JP); Akio Kamikawa, Tokyo (JP); Takuya Washio, Tokyo (JP); Yohei Seki, Tokyo (JP); Keiichiro Okuyama, Tokyo (JP); Osamu Ikeda, Tokyo (JP); Hiroshi Tomiyama, Nagano (JP); Yoshinori Iwai, Nagano (JP); Akihiko Nakamura, Nagano (JP); and Kozo Miyasaka, Nagano (JP)
Assigned to Astellas Pharma Inc., Tokyo (JP); and KOTOBUKI PHARMACEUTICAL CO., LTD., Nagano (JP)
Filed by Astellas Pharma Inc., Tokyo (JP); and Kotobuki Pharmaceutical Co., Ltd., Nagano (JP)
Filed on Nov. 28, 2023, as Appl. No. 18/521,400.
Application 18/521,400 is a continuation of application No. 18/254,829, previously published as PCT/JP2021/043540, filed on Nov. 29, 2021.
Claims priority of application No. 2020-197899 (JP), filed on Nov. 30, 2020.
Prior Publication US 2024/0101532 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/12 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 487/04 (2006.01)

CPC C07D 401/12 (2013.01) [A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/519 (2013.01); A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 487/04 (2013.01)]

14 Claims

1. A compound or a salt thereof, wherein the compound is selected from the group consisting of:

N-{2-[(3S)-3-(aminomethyl)piperidin-1-yl]-4-(2-fluorophenoxy)-3-(trifluoromethyl)phenyl}-1-(2,2-difluoroethyl)-1H-pyrazole-3-carboxamide;

N-{2-[(3S)-3-(aminomethyl)-4-methylpiperazin-1-yl]-4-(2-chlorophenoxy)-3-(trifluoromethyl)phenyl}-1-(2,2-difluoroethyl)-1H-pyrazole-3-carboxamide;

N-{2-[(3S)-3-(aminomethyl)-4-methylpiperazin-1-yl]-3-chloro-4-(2-chlorophenoxy)phenyl}-1-(2,2-difluoroethyl)-1H-pyrazole-3-carboxamide;

N-[4-(2-fluorophenoxy)-2-{(3S)-4-methyl-3-[(methylamino)methyl]-piperazin-1-yl}-3-(trifluoromethyl)phenyl]-1-(pyridazin-4-yl)-1H-pyrazole-3-carboxamide;

N-{2-[(3R)-3-(aminomethyl)-3-fluoropiperidin-1-yl]-4-(2-fluorophenoxy)-3-(trifluoromethyl)phenyl}-1-(pyridazin-4-yl)-1H-pyrazole-3-carboxamide;

N-[4-(2-fluorophenoxy)-2-{(3R)-4-methyl-3-[(methylamino)methyl]piperazin-1-yl}-3-(trifluoromethyl)phenyl]-1-(pyridazin-4-yl)-1H-pyrazole-3-carboxamide;

N-[4-cyclopentyl-2-{(3S)-4-methyl-3-[(methylamino)methyl]piperazin-1-yl}-3-(trifluoromethyl)phenyl]-1-(pyridazin-4-yl)-1H-pyrazole-3-carboxamide;

N-{2-[(8R,8aS)-8-aminohexahydropyrrolo[1,2-a]pyrazine-2(1H)-yl]-4-(2-fluorophenoxy)-3-(trifluoromethyl)phenyl}-2-(pyridazin-4-yl)-1,3-oxazole-4-carboxamide; and

N-[3-chloro-4-(2-fluorophenoxy)-2-{(3S)-4-methyl-3-[(methylamino)methyl]piperazin-1-yl}phenyl]-1-(pyridazin-4-yl)-1H-pyrazole-3-carboxamide.